Scarica l'app Stockscreener
1.18
0.84%
-0.01
Dopo l'orario di chiusura:
1.15
-0.03
-2.54%
Precedente Chiudi:
$1.19
Aprire:
$1.17
Volume 24 ore:
119.53K
Relative Volume:
0.29
Capitalizzazione di mercato:
$4.21M
Reddito:
-
Utile/perdita netta:
$-11.89M
Rapporto P/E:
-0.2095
EPS:
-5.6317
Flusso di cassa netto:
$-10.96M
1 W Prestazione:
-7.81%
1M Prestazione:
-39.18%
6M Prestazione:
-85.25%
1 anno Prestazione:
-91.09%
Intervallo 1D:
$1.14
$1.20
Intervallo di 1 settimana:
$1.14
$1.295
Portata 52W:
$1.14
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Nome
Cadrenal Therapeutics Inc
Settore
Industria
Telefono
904-300-0701
Indirizzo
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
1.18 | 4.25M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Iniziato | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie
Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote, News & History - benzinga.com
Cadrenal Therapeutics announces up to $8.8M private placement - scanx.trade
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference - Yahoo Finance
Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway - TipRanks
Cadrenal Therapeutics (CVKD) Advances Phase 3 Trial Protocol, Fa - GuruFocus
Cadrenal Therapeutics Announces FDA Alignment on Phase 3 Primary Endpoint for CAD-1005 HIT Study - Quiver Quantitative
FDA agrees to a placebo trial for a drug aimed at a blood reaction affecting 50,000 yearly - Stock Titan
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise - Yahoo Finance
Cadrenal's CAD-1005 cuts thrombotic events by over 25% in Phase 2 - scanx.trade
Cadrenal (CVKD) Results Check: EPS Clears the Reported Estimate; After Results: Shares Move 4.09% Down on the DaySlow Growth Warning - vinanet.vn
Cadrenal (CVKD) Latest Earnings Reading: The Bottom-Line Figure Beats Its Comparison in the Current Update; Post-Report Move: Shares Finish 2.29% Lower at the CloseFull Year Guidance - vinanet.vn
Cadrenal Therapeutics (CVKD) Falls 4.28% to $1.79, Pressing Against Key SupportFibonacci Entry Signals - vinanet.vn
Avoiding Lag: Real-Time Signals in (CVKD) Movement - Stock Traders Daily
Cadrenal Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target - TipRanks
Cadrenal Therapeutics data on CAD-1005 accepted for ISTH presentation - scanx.trade
PNC Financial Services Group, Inc. Acquires New Stake in Cadrenal Therapeutics Inc (CVKD) - GuruFocus
Cadrenal Therapeutics appoints John P. Sharp as interim CFO - scanx.trade
Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million - scanx.trade
Cadrenal Therapeutics reports Q2 2026 net loss of $3.3M; cash runway into Q1 2027 - TradingView
Cadrenal CAD-1005 data show more than 25% absolute drop in clot events - Stock Titan
Cadrenal Therapeutics (CVKD) Q1 2026 Earnings: Wider-Than-Expected Loss Buffer Despite Stock DipEstimate Dispersion - Vinanet
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
CVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Cadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound SupportAI Trade Signals - dars.gov.et
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy - Smartkarma
Cadrenal expands CAD-1005 development to two indications - Investing.com
Cadrenal expands CAD-1005 development to two indications By Investing.com - Investing.com India
Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure - Quiver Quantitative
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - Yahoo Finance
Cadrenal Therapeutics (CVKD) Drops 3.8%, Approaches Critical $1.91 SupportMean Reversion Trade - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:1.830|Chg%:-0.030 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.045|Chg%:-0.015 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
TradingKey - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Market Sentiment - Benzinga España
Cadrenal Therapeutics, Inc. Revenue Breakdown – NASDAQ:CVKD - TradingView
CVKD|Cadrenal Therapeutics Inc|Price:2.030|Chg%:-0.010 - TradingKey
Form PRE 14A CADRENAL THERAPEUTICS For: 23 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) seeks approval for 1M-share equity plan and 960K warrant shares - Stock Titan
H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cadrenal seeks partners for cardiac care drug portfolio By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Inc Azioni (CVKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):